The new funding will help accelerate IND-enabling work on Amicidin-β Solution, which targets treatment of serious surgical and traumatic wound infections. It will also support prototyping of a new product, Amicidin-β/EF (Extended Formulation) targeted for prevention of infection in low- and middle-income countries (LMICs), including women undergoing emergency caesarean delivery procedures. Funding for the LMIC product is made possible by the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), a CARB-X partner that supports early-stage innovative research in underfunded areas of R&D to tackle antimicrobial resistance (AMR) for the benefit of people in LMICs.

​

For full press release on the CARB-X website click here.

​